Literature DB >> 30738638

Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics.

Jürgen Scheller1, Erika Engelowski2, Jens M Moll2, Doreen M Floss2.   

Abstract

Cytokines control immune-related events and are critically involved in a plethora of physiological and pathophysiological processes including autoimmunity and cancer development. Accordingly, modulation of natural cytokine signaling by antibodies and small molecules has improved therapeutic regimens. Synthetic biology sets out to optimize immunotherapeutics, with chimeric antigen receptor (CAR) T cell immmunotherapy being the first example to combine synthetic biology with genetic engineering during therapy. Hence, synthetic cytokines and cytokine receptors, as well as constitutively active cytokine receptor variants, are emerging as tools to improve or modulate immunotherapeutic strategies. This review focuses on recent developments in the growing field of synthetic cytokine signaling, providing an outlook for developing applications that involve physiological targets of immunotherapy.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CAR; Cytokine; Cytokine receptor; Immunotherapy; Interleukin

Mesh:

Substances:

Year:  2019        PMID: 30738638     DOI: 10.1016/j.it.2019.01.001

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  7 in total

1.  Synthetic interleukin 22 (IL-22) signaling reveals biological activity of homodimeric IL-10 receptor 2 and functional cross-talk with the IL-6 receptor gp130.

Authors:  Sofie Mossner; Marcus Kuchner; Nastaran Fazel Modares; Birgit Knebel; Hadi Al-Hasani; Doreen M Floss; Jürgen Scheller
Journal:  J Biol Chem       Date:  2020-07-01       Impact factor: 5.157

Review 2.  Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies.

Authors:  Nina B Horowitz; Imran Mohammad; Uriel Y Moreno-Nieves; Ievgen Koliesnik; Quan Tran; John B Sunwoo
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

Review 3.  The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.

Authors:  Xiaohu Zheng; Yaqi Wu; Jiacheng Bi; Yingying Huang; Ying Cheng; Yangyang Li; Yuwei Wu; Guoshuai Cao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2022-01-04       Impact factor: 11.530

4.  Synthetic mimetics assigned a major role to IFNAR2 in type I interferon signaling.

Authors:  Nele Zoellner; Noémi Coesfeld; Frederik Henry De Vos; Jennifer Denter; Haifeng C Xu; Elena Zimmer; Birgit Knebel; Hadi Al-Hasani; Sofie Mossner; Philipp A Lang; Doreen M Floss; Jürgen Scheller
Journal:  Front Microbiol       Date:  2022-09-02       Impact factor: 6.064

5.  The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer.

Authors:  Muhammed Üçüncü; Murat Serilmez; Murat Sarı; Süleyman Bademler; Senem Karabulut
Journal:  Biomolecules       Date:  2019-09-09

6.  Multimerization strategies for efficient production and purification of highly active synthetic cytokine receptor ligands.

Authors:  Sofie Mossner; Hoang T Phan; Saskia Triller; Jens M Moll; Udo Conrad; Jürgen Scheller
Journal:  PLoS One       Date:  2020-04-01       Impact factor: 3.240

7.  Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity.

Authors:  Zhenhua Ren; Anli Zhang; Zhichen Sun; Yong Liang; Jianfeng Ye; Jian Qiao; Bo Li; Yang-Xin Fu
Journal:  J Clin Invest       Date:  2022-02-01       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.